Guggenheim Upgrades Health Catalyst to Buy, Announces $14 Price Target
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Jack Wallace has upgraded Health Catalyst (NASDAQ:HCAT) from Neutral to Buy and set a price target of $14.
January 26, 2024 | 10:31 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Health Catalyst has been upgraded by Guggenheim from Neutral to Buy with a new price target of $14.
Analyst upgrades typically lead to a positive short-term reaction in the stock price as they suggest a better outlook for the company. The new price target of $14 implies a potential upside from the current trading level, which can attract investors.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100